NCT07563335

Brief Summary

This study aims to develop, implement, and evaluate a stage-matched psychosocial intervention to enhance the psychological adaptation of parent caregivers of children with leukemia in Pakistan. The intervention is based on the Transactional Family Adaptation Model and Double ABC-X Model of family stress. It will be tailored to meet the specific emotional and behavioral needs of caregivers at different stages of their child's treatment journey. The study consists of four stages: (1) needs assessment, (2) intervention design, (3) intervention refinement, and (4) a pilot randomized controlled trial. The intervention will be tested at two tertiary care hospitals in Pakistan, with an expected sample size of 88 parent caregivers. Outcomes will assess feasibility, acceptability, and preliminary efficacy in improving psychological adaptation, reducing distress, and enhancing coping skills among caregivers.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for not_applicable

Timeline
7mo left

Started Jun 2025

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Jun 2025Dec 2026

Study Start

First participant enrolled

June 10, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2026

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

April 20, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 4, 2026

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

May 4, 2026

Status Verified

April 1, 2026

Enrollment Period

10 months

First QC Date

April 20, 2026

Last Update Submit

April 28, 2026

Conditions

Keywords

"Parent caregivers""Psychological Adaptation""Childhood leukemia"

Outcome Measures

Primary Outcomes (3)

  • Psychological Adaptation

    The primary outcome measure will assess the psychological adaptation of parent caregivers of children with leukemia. It will be measured using validated scales such as the Psychological Adaptation Scale (PAS), which evaluates the caregiver's emotional response to their child's illness, their coping strategies, and overall psychological adjustment.The scale contains 20 items and 4 dimensions, namely coping ability, self-reliance, social ability and psychological growth. The scale uses the Likert 5-point scoring method, 1 represents strongly disagree and 5 represents strongly agree. The higher the score, the better the psychological adaptation of the caregiver.

    Baseline, Mid-Intervention (Week 6), Post-Intervention (Week 12)

  • Distress

    The level of emotional distress (including depression, anxiety, and stress) will be assessed using the DASS-21 (Depression, Anxiety, Stress Scale). The scale will measure the severity of distress experienced by parent caregivers during the intervention period.This scale consists 21 items, with 7 items per for each of the three scales. For reporting the score of the three scales Depression ( Normal 0-9, Mild 5-6, Moderate 7-10, Sever 11-13 and Extremely severe 14+), Anxiety ( Normal 0-3, Mild 4-5, Moderate 6-7, Sever 8-9 and Extremely severe 10+) and Stress ( Normal 0-7, Mild 8-9, Moderate 10-12, Sever 13-16 and Extremely severe 17+).Higher scores on the DASS-21 indicate worse outcomes (i.e., higher levels of distress, including depression, anxiety, and stress).

    Baseline, Mid-Intervention (Week 6), Post-Intervention (Week 12)

  • Caregiver Burden

    The Caregiver Burden Scale will be used to assess the burden felt by caregivers in terms of time, physical, emotional, and financial strain due to caregiving responsibilities.It contained 22 items assessing experience of burden. The total score is 88 and for reporting the scale is: No or minimal burden ( 0-20) , Mild to moderate burden (21-40), Moderate to severe burden ( 41-60) and severe burden (61-88). Higher scores on the Caregiver Burden Scale indicate worse outcomes (i.e., higher levels of burden or strain experienced by the caregiver).

    Baseline, Mid-Intervention (Week 6), Post-Intervention (Week 12)

Study Arms (2)

Stage-Matched Psychosocial Intervention

EXPERIMENTAL

Parent caregivers in this arm will receive the stage-matched psychosocial intervention in addition to routine medical care over 12 weeks.

Behavioral: Stage-Matched Psychosocial InterventionOther: Routine Medical Care

Routine Medical Care

NO INTERVENTION

Parent caregivers in this arm will receive routine medical care only.

Interventions

This is a culturally adapted, theory-informed psychosocial intervention aimed at improving psychological adaptation and reducing distress among parent caregivers of children with leukemia. The intervention is stage-matched to the caregiver's phase in the child's treatment process and will include psychoeducation, emotional validation, problem-solving skills, and dyadic communication support.

Stage-Matched Psychosocial Intervention

This arm consists of standard medical care provided to caregivers of children diagnosed with leukemia, without any additional psychosocial support intervention. The aim is to compare the outcomes of the intervention group with those receiving routine care.

Stage-Matched Psychosocial Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Parent caregiver (biological parent, step-parent, or legal guardian) primarily responsible for the daily care of a child diagnosed with leukemia.
  • Child is receiving care at one of the participating pediatric oncology study facilities in Pakistan.
  • Caregiver is aged 18 years or older.
  • Caregiver is able to provide written informed consent.
  • Caregiver is willing to participate in the 12-week study and complete study assessments.
  • Caregiver is able to communicate in Urdu or another language used for study procedures at the participating site.

You may not qualify if:

  • Parent caregiver plans to relocate outside the study area during the study period.
  • Parent caregiver is not the primary caregiver of the child with leukemia.
  • Parent caregiver is unable to provide informed consent.
  • Parent caregiver has a severe cognitive, psychiatric, or medical condition that would prevent participation in the intervention or completion of study assessments, as judged by the study team.
  • Parent caregiver is currently participating in another structured psychosocial intervention study that could interfere with this trial.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hayatabad Medical Complex

Peshawar, Khyber Pakhtunkhwa, 25100, Pakistan

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: This is a two-arm pilot cluster-randomized parallel-assignment study. Two pediatric oncology facilities in Pakistan will be assigned to either the stage-matched psychosocial intervention plus routine medical care or routine medical care alone. Cluster randomization at the facility level is used to reduce contamination between participants within the same setting and to support consistent delivery of the intervention by trained staff. Parent caregivers will be assessed at baseline, mid-intervention, and post-intervention over a 12-week study period.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD Scholar

Study Record Dates

First Submitted

April 20, 2026

First Posted

May 4, 2026

Study Start

June 10, 2025

Primary Completion

March 30, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

May 4, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Individual Participant Data (IPD) will not be shared due to privacy concerns and the sensitive nature of the data collected in the study. The data involves personal health information, and the confidentiality of participants will be strictly maintained in accordance with ethical and legal requirements. Additionally, due to the study's specific context in pediatric oncology, data sharing is not currently planned

Locations